CC
ATXS

Clearline Capital’s Astria Therapeutics ATXS Stock Holding History

Clearline Capital’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-780
Closed -$571K – 46
2015
Q2 		$571K Buy
+780
New +$590K 0.08% 64

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Clearline Capital's ATXS Position: Q3 2015 in Review

Clearline Capital sold out of Astria Therapeutics (ATXS) in Q3 2015, closing a stake of 780 shares — an estimated $571K sold.

Clearline Capital first reported a position in ATXS in Q2 2015 and held it in 1 quarter. The position peaked at $571K in Q2 2015. 35 funds tracked by Wall St. Rank hold ATXS as of Q3 2015.

  • Clearline Capital reported no remaining Astria Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Clearline Capital sold 780 Astria Therapeutics shares in Q3 2015, an estimated $571K.
  • Clearline Capital first reported a position in Astria Therapeutics in Q2 2015 and held it in 1 quarter.
  • Clearline Capital's Astria Therapeutics position peaked at $571K in Q2 2015.
  • 35 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2015.

Based on Clearline Capital's 13F filing for Q3 2015, filed 16 Nov 2015.